A
Aris Liakos
Researcher at Aristotle University of Thessaloniki
Publications - 47
Citations - 1971
Aris Liakos is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 17, co-authored 43 publications receiving 1426 citations. Previous affiliations of Aris Liakos include University of Oxford & University of Ioannina.
Papers
More filters
Journal ArticleDOI
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Despoina Vasilakou,Thomas Karagiannis,Eleni Athanasiadou,Maria Mainou,Aris Liakos,Eleni Bekiari,Maria Sarigianni,David R. Matthews,Apostolos Tsapas +8 more
TL;DR: Sodium-glucose cotransporter 2 inhibitors may improve short-term outcomes in adults with type 2 diabetes, but effects on long- term outcomes and safety are unclear.
Journal ArticleDOI
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Aris Liakos,Thomas Karagiannis,Eleni Athanasiadou,Maria Sarigianni,Maria Mainou,Konstantinos Papatheodorou,Konstantinos Papatheodorou,Eleni Bekiari,Apostolos Tsapas,Apostolos Tsapas +9 more
TL;DR: The objective was to assess the efficacy and safety of the novel sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin compared with placebo or other antidiabetic agents in patients with type 2 diabetes.
Journal ArticleDOI
Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms.
Konstantinos I. Bougioukas,Aris Liakos,Apostolos Tsapas,Evangelia E. Ntzani,Anna-Bettina Haidich +4 more
TL;DR: A pilot version checklist with Preferred Reporting Items for OoSRs (PRIO-harms) to promote a more balanced reporting of benefits and harms in Oo SRs of health care interventions and will assist overview authors to improve completeness and transparency of research reporting.
Journal ArticleDOI
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Apostolos Tsapas,Ioannis Avgerinos,Thomas Karagiannis,Konstantinos Malandris,Apostolos Manolopoulos,Panagiotis Andreadis,Aris Liakos,David R. Matthews,Eleni Bekiari +8 more
TL;DR: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes, and in patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes.
Journal ArticleDOI
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Tom C. Karagiannis,Ioannis Avgerinos,Aris Liakos,Stefano Del Prato,David R. Matthews,Apostolos Tsapas,Eleni Bekiari +6 more
TL;DR: Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval as mentioned in this paper .